nach oben

Journal of Nephrology

Erschienen in:

01.02.2018 | Review

Cisplatin nephrotoxicity: a review of the literature

verfasst von: Sandhya Manohar, Nelson Leung

Erschienen in: Journal of Nephrology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Cisplatin is a platinum containing drug first approved as an antineoplastic agent in 1978. It remains an important and effective therapy in many forms of cancer today. Cisplatin mediates its tumorcidal effects via a number of different cytotoxic mechanisms. Although it is best known for DNA damage, cisplatin also causes cytoplasmic organelle dysfunction particularly with the endoplasmic reticulum and mitochondria. It also activates apoptotic pathways and inflicts cellular damage via oxidative stress and inflammation. One of its dose limiting toxicities is its effects on the kidney. This includes acute kidney injury as well as tubular injury resulting in electrolyte wasting. Extensive research has found that cisplatin entry into a cell is facilitated by a number of cellular transporters including human copper transport protein 1 (Ctr1) and the organic cation transporter 2 (OCT2) which are expressed on renal tubular cells. The interactions between the mechanisms of cytotoxicity and cellular transport play an important role in the nephrotoxicity. Better understanding of these interactions could one day help devise better renoprotection that would not reduce its anti-tumor effects.

Prestayko AW, Crooke ST, Carter SK, University of Alabama in Birmingham (1980) Comprehensive Cancer Center., Bristol Laboratories.: Cisplatin, current status and new developments. Academic Press, New York

Liira J, Verbeek JH, Costa G, Driscoll TR, Sallinen M, Isotalo LK, Ruotsalainen JH (2014) Pharmacological interventions for sleepiness and sleep disturbances caused by shift work. Cochrane Database Syst Rev 2014(8):CD009776

Florea AM, Busselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3(1):1351–1371CrossRef

Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994–1007CrossRefPubMed

Townsend DM, Hanigan MH (2002) Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300(1):142–148CrossRefPubMed

Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14(1):1–10CrossRefPubMed

Cozzaglio L, Doci R, Colella G, Zunino F, Casciarri G, Gennari L (1990) A feasibility study of high-dose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer. Tumori 76(6):590–594PubMed

Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O (1989) Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 70(1–2):89–101CrossRefPubMed

Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M (1996) Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16(1):16–39PubMed

10.

Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89(7):3070–3074CrossRefPubMedPubMedCentral

11.

Hanigan MH, Gallagher BC, Townsend DM, Gabarra V (1999) Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis 20(4):553–559CrossRefPubMed

12.

Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14(7):2101–2112CrossRefPubMed

13.

Sastry J, Kellie SJ (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22(5):441–445CrossRefPubMed

14.

Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, Laurell G (2004) High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope 114(9):1660–1667CrossRefPubMed

15.

Esposito M, Viale M, Vannozzi MO, Zicca A, Cadoni A, Merlo F, Gogioso L (1996) Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). Toxicol Appl Pharmacol 140(2):370–377CrossRefPubMed

16.

Viale M, Vannozzi MO, Pastrone I, Mariggio MA, Zicca A, Cadoni A, Cafaggi S, Tolino G, Lunardi G, Civalleri D et al (2000) Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role? J Pharmacol Exp Ther 293(3):829–836PubMed

17.

Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2(11):2490–2518CrossRef

18.

Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4(4):307–320CrossRefPubMed

19.

Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99(9):2467–2498CrossRefPubMed

20.

Cullen KJ, Yang Z, Schumaker L, Guo Z (2007) Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39(1):43–50CrossRefPubMed

21.

Mandic A, Hansson J, Linder S, Shoshan MC (2003) Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278(11):9100–9106CrossRefPubMed

22.

Hirama M, Isonishi S, Yasuda M, Ishikawa H (2006) Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells. Oncol Rep 16(5):997–1002PubMed

23.

Isnard-Bagnis C, Moulin B, Launay-Vacher V, Izzedine H, Tostivint I, Deray G (2005) [Anticancer drug-induced nephrotoxicity]. Nephrol Ther 1(2):101–114CrossRefPubMed

24.

Portilla D, Dai G, McClure T, Bates L, Kurten R, Megyesi J, Price P, Li S (2002) Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int 62(4):1208–1218CrossRefPubMed

25.

Li S, Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, Portilla D (2004) PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 286(3):F572-580.

26.

Qian W, Nishikawa M, Haque AM, Hirose M, Mashimo M, Sato E, Inoue M (2005) Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am J Physiol Cell Physiol 289(6):C1466–C1475CrossRefPubMed

27.

Periyasamy-Thandavan S, Jiang M, Wei Q, Smith R, Yin XM, Dong Z (2008) Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int 74(5):631–640CrossRefPubMed

28.

Fraser M, Bai T, Tsang BK (2008) Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122(3):534–546CrossRefPubMed

29.

Chirino YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61(3):223–242CrossRefPubMed

30.

Ramesh G, Reeves WB (2005) p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289(1):F166–174CrossRefPubMed

31.

Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB, Dong Z (2007) Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73(9):1499–1510CrossRefPubMedPubMedCentral

32.

Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH, Cleton FJ, Osanto S (2004) Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 40(11):1713–1723CrossRefPubMed

33.

Solanki MH, Chatterjee PK, Xue X, Gupta M, Rosales I, Yeboah MM, Kohn N, Metz CN: Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice. Am J Physiol Renal Physiol 2015, 309(1):F35–47CrossRefPubMed

34.

Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J (2010) The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 6(4):224–235CrossRefPubMed

35.

Kono H, Rock KL (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8(4):279–289CrossRefPubMedPubMedCentral

36.

Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB (2008) TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 19(5):923–932CrossRefPubMedPubMedCentral

37.

Tadagavadi RK, Reeves WB (2010) Endogenous IL-10 attenuates cisplatin nephrotoxicity: role of dendritic cells. J Immunol 185(8):4904–4911CrossRefPubMedPubMedCentral

38.

Ramesh G, Reeves WB (2004) Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 65(2):490–499CrossRefPubMed

39.

Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jang KY, Sung MJ, Park SK, Kim W (2009) Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant 24(10):3012–3020CrossRefPubMed

40.

Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Investig 110(6):835–842CrossRefPubMedPubMedCentral

41.

Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99(22):14298–14302CrossRefPubMedPubMedCentral

42.

Pabla N, Murphy RF, Liu K, Dong Z (2009) The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296(3):F505–511

43.

Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48:495–535CrossRefPubMed

44.

Ishida S, McCormick F, Smith-McCune K, Hanahan D (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17(6):574–583CrossRefPubMedPubMedCentral

45.

Jacobs C, Coleman CN, Rich L, Hirst K, Weiner MW (1984) Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Res 44(8):3632–3635PubMed

46.

Klein J, Bentur Y, Cheung D, Moselhy G, Koren G (1991) Renal handling of cisplatin: interactions with organic anions and cations in the dog. Clin Investig Med 14(5):388–394

47.

Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, Sikic BI (1991) The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 67(6):1518–1524CrossRefPubMed

48.

Koepsell H (1998) Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 60:243–266CrossRefPubMed

49.

Koepsell H, Schmitt BM, Gorboulev V (2003) Organic cation transporters. Rev Physiol Biochem Pharmacol 150:36–90CrossRefPubMed

50.

Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86(4):396–402CrossRefPubMedPubMedCentral

51.

Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstadt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH et al (2010) Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176(3):1169–1180CrossRefPubMedPubMedCentral

52.

Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, Schlatter E (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167(6):1477–1484CrossRefPubMedPubMedCentral

53.

Yonezawa A, Inui K (2011) Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 81(5):563–568CrossRefPubMed

54.

Urakami Y, Akazawa M, Saito H, Okuda M, Inui K (2002) cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13(7):1703–1710CrossRefPubMed

55.

Sleijfer DT, Offerman JJ, Mulder NH, Verweij M, van der Hem GK, Schraffordt Koops HS, Meijer S (1987) The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60(11):2823–2828CrossRefPubMed

56.

Goldstein RS, Mayor GH (1983) Minireview. The nephrotoxicity of cisplatin. Life Sci 32(7):685–690CrossRefPubMed

57.

Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C (1999) Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 83(6):866–869CrossRefPubMed

58.

Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65(2):307–314CrossRefPubMed

59.

Maxwell MH, Kleeman CR, Narins RG (1994) Maxwell & Kleeman’s clinical disorders of fluid and electrolyte metabolism, 5th edn. McGraw-Hill, Health Professions Division, New York

60.

Schilsky RL, Anderson T (1979) Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90(6):929–931CrossRefPubMed

61.

Sutton RA, Walker VR, Halabe A, Swenerton K, Coppin CM (1991) Chronic hypomagnesemia caused by cisplatin: effect of calcitriol. J Lab Clin Med 117(1):40–43PubMed

62.

Goldstein RS, Mayor GH, Rosenbaum RW, Hook JB, Santiago JV, Bond JT (1982) Glucose intolerance following cis-platinum treatment in rats. Toxicology 24(3–4):273–280CrossRefPubMed

63.

Kim YK, Byun HS, Kim YH, Woo JS, Lee SH (1995) Effect of cisplatin on renal function in rabbits: mechanism of reduced glucose reabsorption. Toxicol Appl Pharmacol 130(1):19–26CrossRefPubMed

64.

Wangila GW, Nagothu KK, Steward R, 3rd, Bhatt R, Iyere PA, Willingham WM, Sorenson JR, Shah SV, Portilla D (2006) Prevention of cisplatin-induced kidney epithelial cell apoptosis with a Cu superoxide dismutase-mimetic [copper2II(3,5-ditertiarybutylsalicylate)4(ethanol)4]. Toxicol In Vitro 20(8):1300–1312CrossRefPubMed

65.

Swainson CP, Colls BM, Fitzharris BM (1985) Cis-platinum and distal renal tubule toxicity. NZ Med J 98(779):375–378

66.

Safirstein R, Miller P, Dikman S, Lyman N, Shapiro C (1981) Cisplatin nephrotoxicity in rats: defect in papillary hypertonicity. Am J Physiol 241(2):F175–185PubMed

67.

Seguro AC, Shimizu MH, Kudo LH, dos Santos Rocha A (1989) Renal concentration defect induced by cisplatin. The role of thick ascending limb and papillary collecting duct. Am J Nephrol 9(1):59–65CrossRefPubMed

68.

Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM, Yang JP, Rudnick MR, Elfenbein IB, Narins RG (1984) Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 101(1):41–44CrossRefPubMed

69.

Lam M, Adelstein DJ (1986) Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 8(3):164–169CrossRefPubMed

70.

Lajer H, Kristensen M, Hansen HH, Nielsen S, Frokiaer J, Ostergaard LF, Christensen S, Daugaard G, Jonassen TE (2005) Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 56(5):535–542CrossRefPubMed

71.

Portilla D, Li S, Nagothu KK, Megyesi J, Kaissling B, Schnackenberg L, Safirstein RL, Beger RD (2006) Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 69(12):2194–2204CrossRefPubMed

72.

Kim SW, Lee JU, Nah MY, Kang DG, Ahn KY, Lee HS, Choi KC (2001) Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol 12(5):875–882PubMed

73.

Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2):115–124CrossRefPubMed

74.

Goldstein RS, Mayor GH, Gingerich RL, Hook JB, Rosenbaum RW, Bond JT (1983) The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function. Toxicol Appl Pharmacol 69(3):432–441CrossRefPubMed

75.

Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R (1997) Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40(4):293–308CrossRefPubMed

76.

Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5(2):304–309CrossRefPubMed

77.

Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77(10):1677–1682CrossRefPubMedPubMedCentral

78.

Caglar K, Kinalp C, Arpaci F, Turan M, Saglam K, Ozturk B, Komurcu S, Yavuz I, Yenicesu M, Ozet A et al (2002) Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant 17(11):1931–1935CrossRefPubMed

79.

Tanaka H, Ishikawa E, Teshima S, Shimizu E (1986) Histopathological study of human cisplatin nephropathy. Toxicol Pathol 14(2):247–257CrossRefPubMed

80.

Vickers AE, Rose K, Fisher R, Saulnier M, Sahota P, Bentley P (2004) Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 32(5):577–590CrossRefPubMed

81.

Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50(2):147–158CrossRefPubMed

82.

Dekkers IA, Blijdorp K, Cransberg K, Pluijm SM, Pieters R, Neggers SJ, van den Heuvel-Eibrink MM (2013) Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol CJASN 8(6):922–929CrossRefPubMed

83.

Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bokenkamp A, Blufpand H, van Dulmen-den Broeder E, Veening MA, Kremer LC, Jaspers MW: Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 2013(10):CD008944

84.

Li S, Gokden N, Okusa MD, Bhatt R, Portilla D: Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005, 289(2):F469–480CrossRefPubMed

85.

Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S et al (2001) Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 60(6):2118–2128CrossRefPubMed

86.

Rani N, Bharti S, Tomar A, Dinda AK, Arya DS, Bhatia J (2016) Inhibition of PARP activation by enalapril is crucial for its renoprotective effect in cisplatin-induced nephrotoxicity in rats. Free Radic Res 50(11):1226–1236CrossRefPubMed

87.

Price PM, Safirstein RL, Megyesi J: Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol Renal Physiol 2004, 286(2):F378–384CrossRefPubMed

Titel: Cisplatin nephrotoxicity: a review of the literature
verfasst von: Sandhya Manohar
Nelson Leung
Publikationsdatum: 01.02.2018
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 1/2018
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-017-0392-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cisplatin nephrotoxicity: a review of the literature

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

The peritoneal sieving of sodium: a simple and powerful test to rule out the onset of encapsulating peritoneal sclerosis in patients undergoing peritoneal dialysis

A comparative study of the risk profile of hemodialysis patients in a for profit network and in two regional registries of the Italian Society of Nephrology

Extracellular fluid management and hypertension in urban dwelling versus rural dwelling hemodialysis patients

Towards precision nephrology: the opportunities and challenges of genomic medicine

The impact of change of renal replacement therapy modality on sleep quality in patients with end-stage renal disease: a systematic review and meta-analysis

Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin